

Safety Data Sheet Fluoromount/Plus (OSHA)

SECTION 1: Identification

1.1 GHS Product identifier

Product name Fluoromount/Plus (OSHA)

Product number K048, K048-200 Brand Flouromount/Plus

1.3 Recommended use of the chemical and restrictions on use

In Vitro Diagnostic Use

1.4 Supplier's details

Name Diagnostic Biosystems Address 6616 Owens Drive

Pleasanton CA 94588

USA

Telephone (888) 896-3350

email customersupport@dbiosys.com

1.5 Emergency phone number

(925) 484-3350 (9AM-6PM, Monday - Friday, Pacific Standard Time)

SECTION 2: Hazard identification

General hazard statement

No ingredients of this mixture are considered hazardous

2.1 Classification of the substance or mixture

GHS classification in accordance with: OSHA (29 CFR 1910.1200)

Not a hazardous substance or mixture.

2.2 GHS label elements, including precautionary statements

Not a hazardous substance or mixture.

2.3 Other hazards which do not result in classification

Not a hazardous substance or mixture.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Hazardous components

1. Tromethamine

Concentration 0.5 - 1 % (weight)

Other names / synonyms 1,3-Propanediol, 2-amino-2-(hydroxymethyl)-; Tris; Trometamol;

CAS no. 77-86-1

2. SODIUM AZIDE

Concentration 0.025 - 0.05 % (weight)

Other names / synonyms Sodium azide (Na(N3))

EC no. 247-852-1 CAS no. 26628-22-8 Index no. 011-004-00-7

- Acute toxicity, dermal (C.4.2), Cat. 1

- Acute toxicity, inhalation (C.4.3), Cat. 2
- Acute toxicity, oral (C.4.1), Cat. 2
- Specific target organ toxicity (repeated exposure) (C.4.12), Cat. 2
- Hazardous to the aquatic environment, short-term (acute) (chapter 4.1), Cat. 1
- Hazardous to the aquatic environment, long-term (chronic) (chapter 4.1), Cat. 1

3. Polyvinyl alcohol

Concentration 8 - 10 % (weight)

Other names / synonyms Acetic acid ethenyl ester, polymer with ethenol; Ethenol, homopolymer;

CAS no. 25213-24-5

4. 1,4-Diazabicyclo[2.2.2]octane

Concentration 0.2 - 0.4 % (weight)

Other names / synonyms Triethylenediamine

EC no. 205-999-9 CAS no. 280-57-9

- Flammable solids (C.4.20), Cat. 1

- Acute toxicity, oral (C.4.1), Cat. 4

- Skin corrosion/irritation (C.4.4), Cat. 2

- Eye damage/irritation (C.4.5), Cat. 2A
- Specific target organ toxicity (single exposure) (C.4.11), Cat. 3
- Hazardous to the aquatic environment, short-term (acute) (chapter 4.1), Cat. 3
- Hazardous to the aquatic environment, long-term (chronic) (chapter 4.1), Cat. 3

Trade secret statement (OSHA 1910.1200(i))

*The specific chemical identities and/or actual concentrations or actual concentration ranges for one or more listed components are being withheld as trade secrets under the US regulation 29 CFR 1910.1200(i).

SECTION 4: First-aid measures

4.1 Description of necessary first-aid measures

General advice Consult a physician. Show this safety data sheet to the doctor in attendance.

If inhaled If breathed in, move person into fresh air. If not breathing, give artificial

respiration.

Do NOT induce vomiting. Never give anything by mouth to an unconscious

person. Rinse mouth with water. Consult a physician.

In case of skin contact Rinse with plenty of water. Get medical attention if irritation develops and

persists.

In case of eye contact Rinse thoroughly with plenty of water for at least 15 minutes. Get medical

attention if symptoms occur.

If swallowed Call a poison center or doctor if you feel unwell. If vomiting occurs naturally,

have victim lean forward to reduce the risk of aspiration. Do NOT induce vomiting unless directed to do so by medical personnel. Never give anything

by mouth to an unconscious person.

Acute and delayed symptoms and effects: May cause gastrointestinal irritation. Signs/symptoms may include abdominal pain, stomach upset,

nausea, vomiting and diarrhea.

Personal protective equipment for first-aid responders

Ensure adequate ventilation. Use personal protective equipment. For personal

protection see section 8.

4.2 Most important symptoms/effects, acute and delayed

The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

4.3 Indication of immediate medical attention and special treatment needed, if necessary

No data available

SECTION 5: Fire-fighting measures

5.1 Suitable extinguishing media

Use extinguishing media appropriate for surrounding fire.

5.2 Specific hazards arising from the chemical

Version: SDS-0032, Revision: C, Date of issue: 2022-12-02, p. 3 of 10

SODIUM AZIDE: Sodium oxides

1,4-Diazabicyclo[2.2.2]octane: Carbon oxides, Nitrogen oxides (NOx)

5.3 Special protective actions for fire-fighters

Wear self-contained breathing apparatus for firefighting if necessary.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Remove all sources of ignition. Evacuate personnel to safe areas. Beware of vapours accumulating to form explosive concentrations. Vapours can accumulate in low areas. For personal protection see section 8.

Ensure adequate ventilation. Use personal protective equipment. For personal protection see section 8.

Use personal protective equipment. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Remove all sources of ignition. Evacuate personnel to safe areas. Beware of vapours accumulating to form explosive concentrations. Vapours can accumulate in low areas. For personal protection see section 8.

6.2 Environmental precautions

Should not be released into the environment. See Section 12 for additional ecological information.

6.3 Methods and materials for containment and cleaning up

Contain spillage, and then collect with an electrically protected vacuum cleaner or by wet-brushing and place in container for disposal according to local regulations (see section 13).

Reference to other sections

For disposal see section 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Further processing of solid materials may result in the formation of combustible dusts. The potential for combustible dust formation should be taken into consideration before additional processing occurs. Provide appropriate exhaust ventilation at places where dust is formed. For precautions see section 2.2.

7.2 Conditions for safe storage, including any incompatibilities

Keep container tightly closed in a dry and well-ventilated place.

Specific end use(s)

Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

CAS: 26628-22-8 (EC: 247-852-1)

Sodium azide

ACGIH: 0.29 mg/m3 (C); 0.1 ppm (C) hydrazoic acid vapor TLV® inhalation; NIOSH: 0.29 mg/m3 (C); 0.1 ppm (C) hydrazoic acid vapor REL-C inhalation

8.2 Appropriate engineering controls

Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling the product.

Individual protection measures, such as personal protective equipment (PPE) 8.3

Pictograms







Eve/face protection

Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).

Skin protection

Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands.

Body protection

Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and to the specific work-place., The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace.

Respiratory protection

Respiratory protection is not required. Where protection from nuisance levels of dusts are desired, use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).

Thermal hazards

No data available

Control banding approach

No data available.

Environmental exposure controls

Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

SECTION 9: Physical and chemical properties and safety characteristics

Physical state Liquid **Appearance** Clear Color Colorless Odor Odorless Odor threshold No data available.

No data available. Melting point/freezing point

Boiling point or initial boiling point and boiling range Flash point **Evaporation rate**

Flammability Lower and upper explosion limit/flammability limit

Vapor pressure Relative vapor density

Density and/or relative density

No data available. No data available.

No data available.

Version: SDS-0032, Revision: C, Date of issue: 2022-12-02, p. 5 of 10

Solubility
Partition coefficient n-octanol/water (log value)
No data available.
Explosive properties
No data available.

Particle characteristics

No data available.

Supplemental information regarding physical hazard classes

No data available.

Further safety characteristics (supplemental)

No data available.

SECTION 10: Stability and reactivity

10.1 Reactivity

None under normal use conditions.

10.2 Chemical stability

Stable under recommended storage conditions.

10.3 Possibility of hazardous reactions

None under normal use conditions.

10.4 Conditions to avoid

Exposure to moisture.

Avoid storing in direct sunlight and avoid extremes of temperature.

Heat, flames and sparks.

10.6 Hazardous decomposition products

Other decomposition products - No data available In the event of fire: see section 5

SECTION 11: Toxicological information

Information on toxicological effects

Acute toxicity

1,4-Diazabicyclo[2.2.2]octane LD50 Oral - Rat - 700 mg/kg

Sodium azide LD50 Oral - Rat - 27 mg/kg

Skin corrosion/irritation

1,4-Diazabicyclo[2.2.2]octane LD50 Skin - Rabbit - > 2,000 mg/kg

1,4-Diazabicyclo[2.2.2]octane
Draize test - Rabbit - 24 h
Result: Skin irritation

Sodium azide LD50 Skin - Rat - 20 mg/kg

Serious eye damage/irritation

Causes eye irritation.

Respiratory or skin sensitization

Sodium azide

LC50 Inhalation - Rat - 0.054 - 0.52 mg/l - 4 hr

Germ cell mutagenicity

Based on available data, classification data are not met

Carcinogenicity

IARC: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by IARC.

ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by ACGIH.

NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by OSHA.

Reproductive toxicity

Based on available data, classification data are not met

STOT-single exposure

1,4-Diazabicyclo[2.2.2]octane NOAEL - Rat - 100 mg/kg

STOT-repeated exposure

No data available.

Aspiration hazard

No data available.

Additional information

No data available.

SECTION 12: Ecological information

Toxicity

1,4-Diazabicyclo[2.2.2]octane

EC50 - Daphnia magna (water flea) - > 100 mg/l - 48 h

1,4-Diazabicyclo[2.2.2]octane

LC50 - Leuciscus idus (golden orfe) - 681 mg/l - 96 h

1,4-Diazabicyclo[2.2.2]octane

EC50 - Pseudokirchneriella subcapitata (green algae) - 110 mg/l - 72 h

Sodium azide

LC50 - Oncorhynchus mykiss (rainbow trout) - 2.96 mg/l - 96 h

Sodium azide

EC50 - Pseudokirchneriella subcapitata (green algae) - 0.348 mg/l - 96 h

Persistence and degradability

1,4-Diazabicyclo[2.2.2]octane

- 28 d

Result: Result: 7 % - Not readily biodegradable

Bioaccumulative potential

1,4-Diazabicyclo[2.2.2]octane

- Cyprinus carpio (Carp) - 0.1 mg/l - 42 d

Result: Bioconcentration factor (BCF) < 13

Mobility in soil

No data available.

Results of PBT and vPvB assessment

PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

Endocrine disrupting properties

No data available.

Other adverse effects

No data available.

SECTION 13: Disposal considerations

Disposal methods

Product disposal

Offer surplus and non-recyclable solutions to a licensed disposal company.

Packaging disposal

Dispose of as unused product.

Waste treatment

No data available

Sewage disposal

Do not let product enter drains

Other disposal recommendations

Dispose of contents/ container in accordance with the local/regional/national/international regulations.

SECTION 14: Transport information

DOT (US)

Not dangerous goods

IMDG

Not dangerous goods

IATA

Not dangerous goods

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations specific for the product in question

Canadian Domestic Substances List (DSL)

Chemical name: 1,3-Propanediol, 2-amino-2-(hydroxymethyl)-

CAS: 77-86-1

Chemical name: Sodium azide (Na(N3))

CAS: 26628-22-8

Chemical name: Acetic acid ethenyl ester, polymer with ethenol

CAS: 25213-24-5

Chemical name: Ethenol, homopolymer

CAS: 9002-89-5

Chemical name: 1,4-Diazabicyclo[2.2.2]octane

CAS: 280-57-9

Massachusetts Right To Know Components

Chemical name: Sodium azide (Na(N3))

CAS number: 26628-22-8

New Jersey Right To Know Components

Common name: SODIUM AZIDE

CAS number: 26628-22-8

Pennsylvania Right To Know Components

Chemical name: Sodium azide CAS number: 26628-22-8

SARA 311/312 Hazards

Acute Health Hazard

Seveso Directive

Yes. H2 -acute toxic. E1

15.2 Chemical Safety Assessment

The supplier of this product has not conducted any Chemical Safety Assessment

SECTION 16: Other information

SDS-0032, Rev. C

16.1 Further information/disclaimer

DISCLAIMER: The information above is believed to be accurate and represents the best information currently available to us. However, we make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume no liability resulting from its use. Users should make their own

Version: SDS-0032, Revision: C, Date of issue: 2022-12-02, p. 9 of 10

investigation to determine the suitability of information for their particular purposes. In no event shall Diagnostic BioSystems be liable for any claims, losses, or damages of any third party or for lost profits or any special, indirect, incidental, consequential or exemplary damages, whatsoever arising, even if Diagnostic BioSystems has been advised of the possibility of such damages.

Version: SDS-0032, Revision: C, Date of issue: 2022-12-02, p. 10 of 10